Estrifam

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Estrifam

Quick Facts

Property Description
Active ingredient Estradiol (as Estradiol hemihydrate)
Form Film-coated tablet, oral systemic delivery
Pharmacological class Estrogen preparation
Common use Hormone replacement therapy (HRT) for deficiency states
Origin Derived, chemically identical to natural human estrogen

What Type of Medicine is Estrifam (Estradiol)?

Estrifam is a single-ingredient prescription medicine classified as an Estrogen preparation used for Hormone Replacement Therapy (HRT). It is specifically designed to provide the body with a direct source of Estradiol, the principal form of estrogen naturally produced in the human body. This medicine's formulation is clinically recognized for delivering a defined and consistent level of estradiol through the oral route. As a monotherapy, Estrifam delivers only the estrogen component, making it suitable for protocols where supplementary progestogen is administered separately or is not required.

Active Ingredient, Composition, and Origin

The active ingredient in Estrifam is Estradiol, specifically manufactured as Estradiol hemihydrate, and it is presented as an oral film-coated tablet. The Estradiol molecule is crucial because its molecular structure is chemically and biologically identical to 17beta-estradiol, which is the endogenous human estrogen naturally synthesized in the body. This composition provides a form of natural hormone replacement, distinguishing it from older or purely synthetic derivatives. Unlike transdermal patches or gels, the choice of the oral film-coated tablet defines a specific systemic delivery pathway for the hormone.

General Purpose: Restoring Estradiol in Deficiency States

The primary general purpose of Estrifam is to achieve hormone restoration by supplementing the body’s declining supply of Estradiol. This medication works by supplying the crucial hormone that binds to and activates estrogen receptors in various tissues, thereby restoring necessary endocrine signaling. The core beneficial effect is the reversal of the physiological imbalances and symptoms specifically caused by a significant reduction in natural estrogen levels, such as those that occur following menopause. Its efficacy in managing these deficiency states is widely recognized.

Regulatory References

  1. FDA Drug Labeling for Estradiol
  2. NIH/MedlinePlus

What side effects are possible with Estrifam?

Possible side effects and safety information

The safety profile for Estrifam (estradiol) is organized by regulatory bodies to communicate both expected reactions and clinically significant risks associated with systemic estrogen replacement therapy.

Frequency-Classified Adverse Reactions

The official labeling defines adverse effects based on the probability of occurrence in clinical use, reflecting standard regulatory classifications:

  • Very Common (e.g., ge 1/10): Headache, back pain, and joint pain (arthralgia) are among the most frequently documented reactions.
  • Common (e.g., ge 1/100 to < 1/10): Reactions often listed in this category include breast pain/tenderness, nausea, abdominal pain, bloating, and irregular vaginal bleeding or spotting.

Systemic Class Effects and Serious Reactions

Systemic estrogen therapy is associated with a defined set of serious safety concerns, often highlighted in regulatory warnings (Class Effects):

  • Thromboembolic Risks: An increased risk of Venous Thromboembolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), as well as Stroke and Myocardial Infarction, is documented. This risk is noted to be more likely during the first year of use.
  • Malignancy Risks: Increased risks of certain estrogen-dependent malignancies are noted, including Endometrial Cancer (especially with unopposed use in women with a uterus) and Breast Cancer. These risks are formally associated with the duration of exposure.

Safety Restrictions and Special Populations

The medicine is contraindicated by regulatory bodies for use in individuals with a history of thromboembolic events, known or suspected estrogen-dependent malignant tumors, and undiagnosed genital bleeding. Furthermore, an increased risk of probable dementia has been reported in postmenopausal women 65 years and older taking oral combined hormone therapy.

Overdose and Emergency Response

When over-exposure to Estrifam (Estradiol) occurs, the documented clinical manifestations are primarily centered on mild systemic and gastrointestinal disturbances. Regulatory sources indicate that an overdose may present with nausea, vomiting, stomach pain, breast tenderness, and symptoms like dizziness or drowsiness. A key manifestation noted is the possibility of excessive vaginal bleeding, which may begin several days after the intake.

Official regulatory documents classify the risk of serious or life-threatening symptoms as very unlikely. However, this low severity classification does not waive the requirement for action. Regulators mandate that patients must seek immediate medical help upon recognition of over-exposure. This involves contacting local emergency services or a specialized center like the Poison Help hotline right away.

The procedural management described in the official prescribing information relies entirely on symptomatic and supportive treatment. Medical intervention may include monitoring vital signs and conducting blood and urine tests. Notably, no specific antidote is known for estradiol overdosage, and supportive measures such as activated charcoal or intravenous fluids are reserved for extreme cases as determined by medical staff.

Therapeutic Uses of Estrifam

What Estrifam treats: main uses and benefits

Estrifam, which contains the hormone estradiol, is an element of Hormone Replacement Therapy (HRT). It is commonly used to help address the symptoms associated with the hormonal changes following the menopause. The medication is applied in addressing conditions characterized by periods of heightened symptoms resulting from estrogen deficiency.

This medication supports patients during episodes of heightened discomfort. These therapeutic domains include the management of symptom clusters related to physical discomfort, such as hot flushes and night sweats, as well as symptoms that interfere with daily functioning, like sleep disturbances, low mood, and vulvovaginal atrophy (vaginal dryness and irritation). It is also considered relevant for the management of bone health in postmenopausal women.

Estrifam plays a role in managing episodes of heightened symptoms, which assists with maintaining a sense of stability. The goal is to provide supportive relief when symptoms interfere with routine activities. Estradiol treatment helps to relieve the symptoms of estrogen deficiency in postmenopausal women.


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning


Estrifam provides support that helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Official Eligibility for Estrifam Use

Estrifam (estradiol) is primarily indicated for use in postmenopausal women to address symptoms of estrogen deficiency. Eligibility for the medicine is strictly defined by regulatory documents, which establish clear restrictions and absolute prohibitions (contraindications).


Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated and must not be used in individuals with:

  • A current or past history of breast cancer or other estrogen-dependent malignant tumors.
  • A history of or current venous or arterial thromboembolic disease (e.g., blood clots, stroke, heart attack).
  • Undiagnosed abnormal genital bleeding.
  • Acute liver disease or certain metabolic disorders, such as Porphyria.
  • Known hypersensitivity to the active substance.

Restricted and Conditional Use

Population/Condition Regulatory Status
Pregnancy Contraindicated (must be discontinued).
Lactation/Breastfeeding Not recommended.
Children/Adolescents Not indicated for use.
Intact Uterus Conditional Use: Must be combined with a progestogen.

Use is also permitted, but requires careful monitoring in patients with cardiac or renal dysfunction due to the risk of fluid retention, and in patients with mild-to-moderate hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Estrifam, which contains estradiol, has officially documented pharmacokinetic interactions that alter its systemic concentration. The primary basis for these interactions is the drug’s partial metabolism by the Cytochrome P450 3A4 (CYP3A4) enzyme system.

Substances that May Reduce Estradiol Levels

Co-administration with CYP3A4 inducers may reduce the plasma concentrations of estrogens, potentially leading to a decrease in therapeutic effect. Medicines explicitly listed in official labeling include Rifampin, Phenobarbital, and Carbamazepine. The herbal product St. John’s Wort is also documented as an enzyme inducer that may reduce estrogen exposure.

Substances that May Increase Estradiol Levels

Conversely, co-administration with CYP3A4 inhibitors may increase the plasma concentrations of estrogens, which may result in side effects. Specific inhibitors listed include antibiotics like Erythromycin and Clarithromycin, and antifungals such as Ketoconazole and Itraconazole. The food product Grapefruit juice is also documented to inhibit this metabolic pathway.

Estradiol’s Effect on Other Drugs and Restrictions

Estradiol is documented to significantly reduce the plasma concentration of Lamotrigine by inducing its metabolic clearance through glucuronidation. Its use requires monitoring in women on thyroid hormone replacement therapy as it may affect thyroid hormone-binding globulin levels. Use of estrogens is formally contraindicated in women with known liver dysfunction or disease due to constraints on the body's ability to clear the drug. The regulatory profile also notes that consuming large amounts of alcohol may increase the risk for liver damage when taking estradiol.

Mechanism of Action

Estrifam (estradiol) is an orally bioavailable estrogen that functions as a highly specific agonist for the nuclear estrogen receptors, ERalpha and ERbeta. The compound binds to these receptors, forming a ligand-receptor complex which dimerizes and translocates to the cell nucleus. This complex then interacts with Estrogen Response Elements (EREs) on the DNA, initiating transcriptional regulation of specific target genes.

This primary molecular action leads to several distinct system-level consequences. At the bone, the mechanism involves modulation of osteoclast-mediated bone resorption via indirect effects on precursor differentiation. In the liver, the compound influences hepatic synthesis of lipoproteins, specifically altering the concentration of circulating VLDL, LDL, and HDL cholesterol. Furthermore, the molecular activity affects the synthesis and release of nitric oxide in endothelial cells, leading to changes in peripheral vascular tone.

Dosage and Administration Information

How Estrifam is Used: Administration Guidelines

Estrifam is a single-ingredient prescription medicine containing estradiol, used for Hormone Replacement Therapy (HRT). The instructions below detail the administration and dosing for this medication.


Administration and Dosage

Estrifam is administered via the oral route as a film-coated tablet. It is available in strengths of 1 mg and 2 mg (Estradiol as hemihydrate). The tablets must be swallowed whole with water and should not be chewed.

Dosing Parameter Guidance
Route & Form Oral film-coated tablet
Starting Dose 1 mg or 2 mg daily
Dosing Frequency One tablet daily without interruption
Optimal Timing Preferably taken at the same time each day

Use Protocol and Dosing Adjustments

Treatment should generally be initiated using the lowest effective dose and continued for the shortest duration consistent with treatment goals, with continuation re-evaluated annually.

Dose Adjustment: The initial dose may be adjusted after two to three months based on individual response, with the aim of reducing the dose to 1 mg daily as soon as practicable.

Co-Administration Requirement: Women with an intact uterus must use Estrifam in combination with a progestagen for at least 10 to 14 consecutive days of a 28-day cycle. The addition of a progestagen is not recommended for hysterectomized women, except in cases of known endometriosis.

Missed Dose Protocol: If a daily dose is forgotten, it should be taken within the next 12 hours. If more than 12 hours have passed, the missed tablet must be discarded, and the patient should continue the regimen with the next scheduled tablet to avoid accidental double-dosing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Estrifam


Evidence for Use in Managing Vasomotor Symptoms

Research exploring short-term symptom changes, primarily through Randomized Controlled Trials (RCTs), was the foundation for evaluating oral estradiol in this setting. The evidence base includes trials where estradiol was compared to an inactive pill (placebo) and trials that monitored outcomes across various hormone preparations. Studies monitored outcomes related to physical discomfort, specifically measuring how symptoms evolved in the observed populations during the study period. Studies contribute to the broader evidence landscape related to symptom patterns in conditions involving periods of heightened symptoms.

Studies reported measurements of change in the mean weekly frequency and severity scores for VMS from the start of the study. Limited specific experience and clinical trial data are available for women aged over 65 or those significantly distant from the onset of menopause. Furthermore, the relevance of findings from older, high-dose hormone therapy trials to the currently used, typically lower-dose regimens is a subject of ongoing investigation.


Evidence for Use in Preventing Postmenopausal Bone Loss

Evidence comes from long-term studies, including cohort studies and meta-analyses, that have focused on measurements related to oral estradiol on Bone Mineral Density (BMD) and the incidence rates of fractures. Research examined populations at risk of low bone mass, monitoring the percent change in BMD at the lumbar spine and hip. Long-term observational cohorts also tracked the incidence rate of fractures occurring in the studied populations over several years. This evidence contributes to the broader evidence landscape by providing context on how bone health markers were monitored in different study settings.

Data show patterns related to a change in BMD measurements. The evidence regarding fracture incidence often relies on data from older, large-scale trials that included various hormone regimens, not solely dedicated fracture RCTs involving the current oral estradiol formulation. Comparative evidence is lacking against newer alternative treatments, and subgroup findings are uncertain regarding the optimal duration of treatment for monitoring bone benefits.


Key Uncertainties and Research Gaps

Primary research limitations include that the results apply only to the populations studied, and sample sizes were modest in some key registration trials. Evidence quality varies across studies, leading to findings where certainty remains low for certain long-term outcomes. Research is ongoing to better characterize the full spectrum of long-term physiological changes, especially in areas where follow-up durations were limited.

Key Studies & References

  1. Estradiol Oral: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Estrifam (FAQ)


Q: How long does it usually take for Estrifam to start working for hot flashes?

A: Studies and official information indicate that improvements in the frequency and severity of hot flashes often begin within the first few weeks of starting oral estrogen therapy. Individual experience with symptom relief can vary. Official product information notes that the dose is typically assessed after two to three months based on individual response.


Q: Can Estrifam help with mood swings during menopause?

A: Estrifam is primarily indicated to relieve physical symptoms caused by estrogen deficiency. While official labeling does not indicate Estrifam as a primary treatment for severe mood disorders, the relief of symptoms like hot flashes may indirectly help with associated issues such as sleep disturbances. It is not specifically indicated for the treatment of mood swings.


Q: Are weight gain or bloating common side effects of Estrifam?

A: Bloating and breast tenderness are listed in the official product information as Common adverse reactions, meaning they affect more than 1 in 100 people. In addition to bloating, official drug labeling has reported changes in body weight among the potential side effects associated with oral estrogen use.


Q: What happens if I accidentally miss a dose of Estrifam?

A: According to official instructions, if a scheduled dose is missed by more than 12 hours, the tablet is to be discarded. The regimen is then continued with the next scheduled tablet at the regular time to avoid accidental double-dosing. Skipping a dose may increase the likelihood of spotting or breakthrough bleeding.


Q: How quickly do the benefits of Estrifam wear off if I stop taking it?

A: The return of symptoms (such as hot flashes) is a likely occurrence once hormone levels decrease after discontinuing the medication. Risks associated with therapy generally decrease upon cessation.


Q: Is Estrifam effective for vaginal dryness and discomfort?

A: Yes, official drug indications confirm that estradiol is indicated for the treatment of vulvar and vaginal atrophy, which includes symptoms such as dryness and discomfort. The medicine addresses these genitourinary symptoms of menopause.


Q: What is the risk of gallstones or gallbladder problems with Estrifam?

A: Official labeling reports that an increased risk of gallbladder disease requiring surgery has been associated with estrogen use in postmenopausal women. This is a systemic risk factor to be aware of during treatment.


Q: Can I take pain relievers like ibuprofen while on Estrifam?

A: The official interaction documentation focuses on strong enzyme inducers and inhibitors, like certain antibiotics or St. John's Wort, that can alter Estrifam's concentration. Common over-the-counter pain relievers like ibuprofen are not typically listed as a known interaction. However, caution is always warranted when combining any medication or supplement.


Q: Can I take herbal supplements like Black Cohosh with Estrifam?

A: Official product information explicitly notes that the herbal product St. John’s Wort can reduce the estrogen levels in your body. Other herbal supplements, such as Black Cohosh, are not officially listed, but can still interact with prescription medications. Therefore, caution should be exercised when considering their use.


Q: Does Estrifam affect my sleep quality?

A: Some patients have reported sleep problems, such as insomnia or trouble sleeping, as potential side effects of oral estrogen therapy. Conversely, by addressing symptoms like night sweats, it may help to improve sleep quality by addressing symptoms that cause sleep disturbances during menopause.


Q: Why is Estrifam often prescribed as part of hormone replacement therapy (HRT)?

A: Estrifam is widely prescribed because it is a single-ingredient drug containing Estradiol, which is chemically identical to the main estrogen naturally produced by the human body. It is recognized for delivering a specific dose of estradiol to address deficiency states as part of hormone restoration therapy.


Q: Does alcohol interact with Estrifam?

A: The regulatory profile for estradiol notes a specific warning that consuming large amounts of alcohol may increase the risk of liver damage while taking the medicine. Consulting a healthcare professional regarding alcohol consumption is advised.


Q: Is Estrifam the same as Estrace?

A: Both Estrifam and Estrace are brand names for tablets that contain the identical active ingredient: Estradiol. Estrifam is a brand name used primarily in European and other non-U.S. regions, while Estrace is a brand name commonly recognized and approved in the United States.


Q: Can Estrifam make you feel tired or dizzy?

A: Official product information lists dizziness as a common side effect of oral estrogen therapy. While tiredness or fatigue are also sometimes reported, headache is classified as a very common adverse reaction.


Q: Why do some people use Estrifam for osteoporosis prevention?

A: Estrifam is approved for the prevention of postmenopausal bone loss because its molecular mechanism helps regulate bone maintenance. Specifically, it works by reducing bone breakdown, which is an important action for maintaining bone mineral density.


Q: What are the signs that Estrifam might not be working for me?

A: The official dosing guidelines note that treatment response is typically reviewed after two to three months. A failure to achieve satisfactory symptom relief, such as persistent, bothersome vasomotor symptoms, may be noted as an insufficient response.


Q: How long can a person safely stay on Estrifam?

A: Regulatory guidance states that treatment should be continued for the shortest duration that is consistent with the patient's treatment goals. Continuation should be re-evaluated annually, as the risk of certain serious conditions is formally associated with the overall duration of estrogen exposure.


Q: Can I take vitamins or minerals at the same time as Estrifam?

A: Official interaction information focuses on substances that strongly affect the drug’s metabolism in the liver. General vitamin and mineral supplements are not explicitly listed as a source of clinically significant interaction. However, all supplements and medications should be discussed with a healthcare professional.


Q: Is Estrifam safe for women who smoke?

A: Official regulatory labeling includes a strong warning that smoking greatly increases the risk of serious side effects while using this medicine, specifically blood clots, stroke, or heart attack. Smoking is a risk factor that must be considered during clinical risk management.


Q: What should I do if I think I'm having an allergic reaction to Estrifam?

A: If you experience any signs of a severe allergic reaction (hypersensitivity), such as difficulty breathing, swelling of the face, throat, or tongue, or hives, emergency medical help should be sought immediately. Hypersensitivity to the active ingredient is an absolute restriction for use.

How should Estrifam be stored and disposed of?

Estrifam (estradiol hemihydrate) tablets must be stored and handled according to official regulatory guidelines to maintain stability and ensure safety.

Storage Requirements

The product must be kept out of the sight and reach of children.

Storage Condition Requirement
Temperature Store below 25 C.
Protection Do not refrigerate. Protect from light and moisture.
Packaging Store in the original container until the date of expiration (EXP).

Disposal Instructions

Unused or expired Estrifam must not be disposed of via wastewater or household waste. The active ingredient, estradiol, is known to pose a potential risk to the aquatic environment. Therefore, any remaining medicinal product or waste material should be returned to a pharmacist or disposed of in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Estrifam found in:

A-Z Index: